N Engl J Med 2014 Sep 27
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer.
Related Questions
Should mutations other then EGFR and ALK be routinely tested for? Should next generation sequencing be routinely done?
New answer by Medical Oncologist at University of Texas MD Anderson Cancer Center (March 11, 2015)
The easy answer to this question is that the only molecular alterations for which we have matched FDA-approved drugs for those specific indications are EGFR and ALK, so the st...
If starting with entrectinib would you still try crizotinib, or move to lorlatinib or another novel TKI? Or change entirely to chemotherapy, immunothe...
New answer by Medical Oncologist at University of California Los Angeles (July 8, 2021)
There is no strong evidence to suggest moving between crizotinib and entrectinib. Using lorlatinib is reasonable, but the response rate is likely lower than with a platinum do...
New answer by Medical Oncologist at Wexner Medical Center at The Ohio State University (August 31, 2019)
The recognition of ROS1 as a distinct actionable translocation in NSCLC, and approval of crizotinib in 2016 based upon an expansion cohort of the original phase I study of cri...